Study guide

5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

Key Takeaways Explain This Topic AI

The cell-based model describes coagulation in three overlapping phases on cell surfaces: initiation (tissue factor-factor VIIa on a cell surface), amplification (thrombin activates platelets and factors V, VIII and XI) and propagation (a burst of thrombin on activated platelets).

The prothrombin time tests the extrinsic and common pathways (factors VII, X, V, II and fibrinogen), whereas the activated partial thromboplastin time tests the intrinsic and common pathways (XII, XI, IX, VIII, X, V, II and fibrinogen).

Factor VII has the shortest half-life of the coagulation factors (about 4-6 hours), so the INR rises first in warfarin therapy, vitamin K deficiency and acute liver failure.

Antithrombin, protein C with protein S, and tissue factor pathway inhibitor are the main natural anticoagulants; heparin works by accelerating antithrombin about 1,000-fold.

Von Willebrand disease is the most common inherited bleeding disorder (up to about 1% of people on laboratory testing); type 1 often responds to desmopressin, which releases von Willebrand factor and factor VIII from endothelial stores.

Last updated: October 2026

  • 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
  • Why Haemostasis Matters

Bleeding and thrombosis are central to perioperative medicine. EDAIC questions test the physiology of clot formation, the meaning of each laboratory test, the effect of hypothermia and acidosis, and the management of inherited disorders. A clear model of coagulation also explains how anticoagulants and their reversal agents work.

Primary Haemostasis: Vessel and Platelets

When the endothelium is breached, subendothelial collagen and von Willebrand factor (vWF) are exposed.

Adhesion: Platelet glycoprotein Ib-IX-V binds vWF; glycoprotein VI and Ia/IIa bind collagen directly.

Activation: Platelets change shape and release granules: dense granules contain ADP, serotonin and calcium; alpha granules contain fibrinogen, vWF and factor V. Thromboxane A2 is synthesised through cyclo-oxygenase-1.

Aggregation: ADP (through P2Y12 receptors), thromboxane A2 and thrombin activate the glycoprotein IIb/IIIa receptor, which binds fibrinogen and links platelets together.

Normal platelet count is about 150 − 400 × 10 9 / L 150-400 \times 10^9/\text{L} 150 − 400 × 1 0 9 / L , and the platelet life span is about 7-10 days. The intact endothelium stays non-thrombogenic by releasing prostacyclin and nitric oxide , expressing thrombomodulin , and carrying heparan sulphate on its surface.

Secondary Haemostasis: The Cell-Based Model

The classical cascade (extrinsic, intrinsic and common pathways) explains laboratory tests but not bleeding in vivo. The cell-based model describes three overlapping phases: 1. INITIATION (tissue factor-bearing cell, e.g. fibroblast)

  • Tissue factor + factor VIIa --> activates X and IX
  • Xa + Va --> small amount of thrombin
  • 2. AMPLIFICATION (platelet surface)
  • Thrombin activates platelets, factors V, VIII and XI,
  • and releases VIII from von Willebrand factor
  • 3. PROPAGATION (activated platelet surface)
  • Tenase (IXa + VIIIa) --> large amounts of Xa
  • Prothrombinase (Xa + Va) --> thrombin burst
  • Thrombin converts fibrinogen to fibrin; XIIIa cross-links it

Key points:

Calcium (factor IV) and phospholipid surfaces are needed for the tenase and prothrombinase complexes.

Factor XII is not needed for haemostasis in vivo: deficiency prolongs the aPTT but does not cause bleeding.

Vitamin K-dependent factors are II, VII, IX and X, plus proteins C and S. Vitamin K allows gamma-carboxylation of glutamate residues so these proteins can bind calcium.

Factor XIII cross-links fibrin; deficiency causes bleeding with normal routine tests.

Natural Anticoagulants and Fibrinolysis

  • System Mechanism
  • Antithrombin Inactivates thrombin and Xa (and IXa, XIa); heparin accelerates it about 1,000-fold

Protein C and protein S Thrombin bound to thrombomodulin activates protein C, which with protein S inactivates Va and VIIIa

Tissue factor pathway inhibitor Inhibits the tissue factor-VIIa-Xa complex

Fibrinolysis Tissue plasminogen activator converts plasminogen to plasmin, which degrades fibrin into D-dimers and fibrin degradation products

Plasmin is inhibited by alpha-2 antiplasmin ; plasminogen activator inhibitor-1 opposes tissue plasminogen activator. Tranexamic acid blocks the lysine-binding sites on plasminogen, preventing it from binding to fibrin.

Factor V Leiden makes factor Va resistant to activated protein C and is the commonest inherited thrombophilia in people of European origin (about 3-8% are heterozygous).

Laboratory Tests

Test Measures Prolonged by Normal value (approximate)

Prothrombin time (PT) / INR VII, X, V, II, fibrinogen Warfarin, vitamin K deficiency, liver disease, DIC PT 11-14 s; INR 0.8-1.2

Activated partial thromboplastin time (aPTT) XII, XI, IX, VIII, X, V, II, fibrinogen Unfractionated heparin, haemophilia, lupus anticoagulant (paradoxically pro-thrombotic) 25-35 s

  • Thrombin time Conversion of fibrinogen to fibrin Heparin, dabigatran, low fibrinogen 12-16 s
  • Fibrinogen (Clauss) Functional fibrinogen Consumption, dilution 2-4 g/L (4-6 g/L at term)
  • Anti-Xa activity Effect of LMWH, fondaparinux, rivaroxaban, apixaban (drug-calibrated) Drug-specific ranges

The INR standardises the PT for warfarin monitoring using the reagent's International Sensitivity Index; it is less reliable in liver disease.

Factor VII has the shortest half-life (about 4-6 hours), so the INR rises first when vitamin K-dependent factors fall.

Mixing studies: if a prolonged aPTT corrects with normal plasma, a factor deficiency is likely; if not, an inhibitor (for example lupus anticoagulant) is present.

Standard tests are performed at 37 °C on plasma, so they underestimate the effect of hypothermia and do not assess platelet function or fibrinolysis. Viscoelastic tests (ROTEM, TEG) assess whole-blood clot formation and lysis at the bedside.

Effects of Hypothermia, Acidosis and Hypocalcaemia

Hypothermia below about 34 °C slows enzyme activity and impairs platelet function.

Acidosis with pH below about 7.2 reduces the activity of the tenase and prothrombinase complexes.

Ionised calcium below about 0.9 mmol/L impairs coagulation; massive transfusion lowers it through citrate.

These three factors form the "lethal triad" with coagulopathy in trauma.

Inherited Bleeding Disorders

Disorder Defect Inheritance Tests Perioperative management

Von Willebrand disease Low or abnormal vWF (type 1 partial deficiency, type 2 qualitative, type 3 severe) Usually autosomal dominant (type 3 recessive) Normal or prolonged aPTT, low vWF antigen and activity Desmopressin 0.3 μ g/kg \mu\text{g/kg} μ g/kg for responsive type 1; vWF-containing concentrate for others; tranexamic acid

Haemophilia A Factor VIII deficiency X-linked recessive Prolonged aPTT, normal PT Recombinant factor VIII to target levels (often 80-100% for major surgery); emicizumab prophylaxis affects aPTT-based tests

  • Haemophilia B Factor IX deficiency X-linked recessive Prolonged aPTT, normal PT Recombinant factor IX
  • Factor XI deficiency Factor XI Autosomal Prolonged aPTT Tranexamic acid, plasma or factor XI concentrate

Desmopressin (DDAVP) releases vWF and factor VIII from endothelial Weibel-Palade bodies. It raises levels two- to fourfold within about 30-60 minutes. Repeated doses cause tachyphylaxis and water retention with hyponatraemia, so fluids should be restricted. It is also used for uraemic platelet dysfunction and mild haemophilia A.

Acquired Disorders

Disseminated intravascular coagulation (DIC): widespread activation consumes platelets and factors; PT and aPTT are prolonged, fibrinogen is low and D-dimers are high. Treat the cause and replace components when bleeding.

Liver disease: both procoagulant and anticoagulant factors fall, so the INR overstates the bleeding risk; the haemostatic balance is "rebalanced" but fragile.

Heparin-induced thrombocytopenia: antibodies against platelet factor 4-heparin complexes cause a fall in platelets 5-10 days after exposure and paradoxical thrombosis.